Sekhoacha M, Riet K, Motloung P, Gumenku L, Adegoke A, Mashele S. Prostate Cancer Review: Genetics, diagnosis, Treatment options, and alternative approaches. Molecules. 2022;27:5730.

Article  CAS  PubMed Central  Google Scholar 

Litwin MS, Tan HJ. The diagnosis and treatment of prostate Cancer: a review. JAMA. 2017;317:2532–42.

Article  Google Scholar 

Bergengren O, Pekala KR, Matsoukas K, Fainberg J, Mungovan SF, Bratt O, Bray F, Brawley O, Luckenbaugh AN, Mucci L, Morgan TM, Carlsson SV. 2022 update on prostate Cancer epidemiology and risk Factors-A systematic review. Eur Urol. 2023;84:191–206.

Article  Google Scholar 

Mumuni S, O’Donnell C, Doody O. The risk factors and screening uptake for prostate Cancer: a scoping review. Healthc (Basel). 2023;11:2780.

Google Scholar 

Taylor AK, Kosoff D, Emamekhoo H, Lang JM, Kyriakopoulos CE. PARP inhibitors in metastatic prostate cancer. Front Oncol. 2023;13:1159557.

Article  CAS  PubMed Central  Google Scholar 

Huebner NA, Shariat SF, Resch I, Gust K, Kramer G. The role of taxane-based chemotherapy in the treatment of prostate cancer. Curr Opin Urol. 2020;30:527–33.

Article  Google Scholar 

Quinn DI, Sandler HM, Horvath LG, Goldkorn A, Eastham JA. The evolution of chemotherapy for the treatment of prostate cancer. Ann Oncol. 2017;28:2658–69.

Article  CAS  Google Scholar 

Vaishampayan UN, Heilbrun LK, Monk P 3rd, Tejwani S, Sonpavde G, Hwang C, Smith D, Jasti P, Dobson K, Dickow B, Heath EI, Semaan L, Cher ML, Fontana JA, Chinni S. Clinical efficacy of Enzalutamide vs Bicalutamide Combined with Androgen Deprivation Therapy in Men with metastatic hormone-sensitive prostate Cancer: a Randomized Clinical Trial. JAMA Netw Open. 2021;4:e2034633.

Article  PubMed Central  Google Scholar 

Shore N, Mellado B, Shah S, Hauke R, Costin D, Adra N, Cullberg M, Teruel CF, Morris T. A phase I study of Capivasertib in Combination with Abiraterone acetate in patients with metastatic castration-resistant prostate Cancer. Clin Genitourin Cancer. 2023;21:278–85.

Article  Google Scholar 

Sella A, Kilbourn R, Amato R, Bui C, Zukiwski AA, Ellerhorst J, Logothetis CJ. Phase II study of ketoconazole combined with weekly doxorubicin in patients with androgen-independent prostate cancer. J Clin Oncol. 1994;12:683–8.

Article  CAS  Google Scholar 

Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S, Johnson EF, Marsh KC, Mitten MJ, Nimmer P, Roberts L, Tahir SK, Xiao Y, Yang X, Zhang H, Fesik S, Rosenberg SH, Elmore SW. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 2008;68(9):3421–8.

Article  CAS  Google Scholar 

Shi J, Zhou Y, Huang HC, Mitchison TJ. Navitoclax (ABT-263) accelerates apoptosis during drug-induced mitotic arrest by antagonizing Bcl-xL. Cancer Res. 2011;71:4518–26.

Article  CAS  PubMed Central  Google Scholar 

Mohamad Anuar NN, Nor Hisam NS, Liew SL, Ugusman A. Clinical review: Navitoclax as a pro-apoptotic and anti-fibrotic Agent. Front Pharmacol. 2020;11:564108.

Article  PubMed Central  Google Scholar 

Özgür A, Tutar Y. Heat shock protein 90 inhibition in Cancer Drug Discovery: from Chemistry to Futural Clinical Applications. Anticancer Agents Med Chem. 2016;16:280–90.

Article  Google Scholar 

Gümus M, Ozgur A, Tutar L, Disli A, Koca I, Tutar Y, Design. Synthesis, and evaluation of heat shock protein 90 inhibitors in human breast Cancer and its metastasis. Curr Pharm Biotechnol. 2016;17:1231–45.

Article  Google Scholar 

Costa TEMM, Raghavendra NM, Penido C. Natural heat shock protein 90 inhibitors in cancer and inflammation. Eur J Med Chem. 2020;189:112063.

Article  CAS  Google Scholar 

Özgür A, Kara A, Gökşen Tosun N, Tekin Ş, Gökçe İ. Debio-0932, a second generation oral Hsp90 inhibitor, induces apoptosis in MCF-7 and MDA-MB-231 cell lines. Mol Biol Rep. 2021;48:3439–49.

Article  Google Scholar 

Isambert N, Delord JP, Soria JC, Hollebecque A, Gomez-Roca C, Purcea D, Rouits E, Belli R, Fumoleau P. Debio0932, a second-generation oral heat shock protein (HSP) inhibitor, in patients with advanced cancer-results of a first-in-man dose-escalation study with a fixed-dose extension phase. Ann Oncol. 2015;26:1005–11.

Article  CAS  Google Scholar 

Moya L, Walpole C, Rae F, Srinivasan S, Seim I, Lai J, Nicol D, Williams ED, Clements JA, Batra J. Characterisation of cell lines derived from prostate cancer patients with localised disease. Prostate Cancer Prostatic Dis. 2023;26:614–24.

Article  PubMed Central  Google Scholar 

Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010;70:440–6.

Article  CAS  Google Scholar 

Pearson RA, Wicha SG, Okour M. Drug combination modeling: methods and applications in Drug Development. J Clin Pharmacol. 2023;63:151–65.

Article  CAS  Google Scholar 

Sun W, Sanderson PE, Zheng W. Drug combination therapy increases successful drug repositioning. Drug Discov Today. 2016;21:1189–95.

Article  CAS  PubMed Central  Google Scholar 

Gilad Y, Gellerman G, Lonard DM, O’Malley BW. Drug combination in Cancer Treatment-from cocktails to conjugated combinations. Cancers (Basel). 2021;13:669.

Article  CAS  Google Scholar 

Bayat Mokhtari R, Homayouni TS, Baluch N, Morgatskaya E, Kumar S, Das B, Yeger H. Combination therapy in combating cancer. Oncotarget. 2017;8:38022–43.

Article  Google Scholar 

Chessum N, Jones K, Pasqua E, Tucker M. Recent advances in cancer therapeutics. Prog Med Chem. 2015;54:1–63.

Article  Google Scholar 

Nor Hisam NS, Ugusman A, Rajab NF, Ahmad MF, Fenech M, Liew SL, Mohamad Anuar NN. Combination therapy of Navitoclax with Chemotherapeutic agents in Solid tumors and Blood Cancer: a review of current evidence. Pharmaceutics. 2021;13:1353.

Article  CAS  PubMed Central  Google Scholar 

Langendonk M, Smit NAM, Plattel W, Diepstra A, Meerten TV, Visser L. Navitoclax Most Promising BH3 Mimetic for Combination Therapy in Hodgkin Lymphoma. Int J Mol Sci. 2022;23:13751.

Article  CAS  PubMed Central  Google Scholar 

Seggewiss-Bernhardt R, Bargou RC, Goh YT, Stewart AK, Spencer A, Alegre A, Bladé J, Ottmann OG, Fernandez-Ibarra C, Lu H, Pain S, Akimov M, Iyer SP. Phase 1/1B trial of the heat shock protein 90 inhibitor NVP-AUY922 as monotherapy or in combination with bortezomib in patients with relapsed or refractory multiple myeloma. Cancer. 2015;121:2185–92.

Article  CAS  Google Scholar 

Johnson ML, Yu HA, Hart EM, Weitner BB, Rademaker AW, Patel JD, Kris MG, Riely GJ. Phase I/II study of HSP90 inhibitor AUY922 and Erlotinib for EGFR-Mutant Lung Cancer with Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors. J Clin Oncol. 2015;33:1666–73.

Article  CAS  PubMed Central  Google Scholar 

Pillai RN, Fennell DA, Kovcin V, Ciuleanu TE, Ramlau R, Kowalski D, Schenker M, Yalcin I, Teofilovici F, Vukovic VM, Ramalingam SS. Randomized Phase III Study of Ganetespib, a heat shock protein 90 inhibitor, with Docetaxel Versus Docetaxel in Advanced Non-small-cell Lung Cancer (GALAXY-2). J Clin Oncol. 2020;38:613–22.

Article  CAS  Google Scholar 

Fennell DA, Danson S, Woll PJ, Forster M, Talbot D, Child J, Farrelly L, Sharkey A, Busacca S, Ngai Y, Hackshaw A, Wheeler GM. Ganetespib in Combination with Pemetrexed-Platinum Chemotherapy in patients with Pleural Mesothelioma (MESO-02): a phase ib trial. Clin Cancer Res. 2020;26:4748–55.

Article  CAS  Google Scholar 

Lossi L. The concept of intrinsic versus extrinsic apoptosis. Biochem J. 2022;479:357–84.

Article  CAS  Google Scholar 

Jan R, Chaudhry GE. Understanding apoptosis and apoptotic pathways targeted Cancer therapeutics. Adv Pharm Bull. 2019;9:205–18.

Article  CAS  PubMed Central  Google Scholar 

Xu X, Lai Y, Hua ZC. Apoptosis and apoptotic body: disease message and therapeutic target potentials. Biosci Rep. 2019;39:BSR20180992.

Article  CAS  PubMed Central  Google Scholar 

Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol. 2007;35:495–516.

Article  CAS  PubMed Central  Google Scholar 

Mori M, Hitora T, Nakamura O, Yamagami Y, Horie R, Nishimura H, Yamamoto T. Hsp90 inhibitor induces autophagy and apoptosis in osteosarcoma cells. Int J Oncol. 2015;46:47–54.

Article  CAS  Google Scholar 

D’Arcy MS. Cell death: a review of the major forms of apoptosis, necrosis and autophagy. Cell Biol Int. 2019;43:582–92.

Article  Google Scholar 

Smets LA. Programmed cell death (apoptosis) and response to anti-cancer drugs. Anticancer Drugs. 1994;5:3–9.

Article  CAS  Google Scholar 

Hickman JA. Apoptosis induced by anticancer drugs. Cancer Metastasis Rev. 1992;11:121–39.

Article  CAS  Google Scholar 

Liu X, Chen S, Tu J, Cai W, Xu Q. HSP90 inhibits apoptosis and promotes growth by regulating HIF-1α abundance in hepatocellular carcinoma. Int J Mol Med. 2016;37:825–35.

Article  CAS  Google Scholar 

Wang X, Chen M, Zhou J, Zhang X. HSP27, 70 and 90, anti-apoptotic proteins, in clinical cancer therapy (review). Int J Oncol. 2014;45:18–30.

Article  Google Scholar 

Karademir D, Özgür A. The effects of STA-9090 (Ganetespib) and venetoclax (ABT-199) combination on apoptotic pathways in human cervical cancer cells. Med Oncol. 2023;40(8):234.

Article  CAS  Google Scholar